Recent Progresses in Immune Cell Therapy for Tuberculosis
Microbial Pathogenesis · 2026-11 · 108915
DOI: 10.1016/j.micpath.2026.108915 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbial Pathogenesis, 2026-11. Verfasst von Jiawen He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Techno…. Die Arbeit nennt 154 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Provincial Natural Science Foundation.
Abstract (Originalsprache)
Tuberculosis (TB) remains a leading cause of global mortality. Its prevention and control face major challenges, including a large latent infection reservoir, high transmissibility, complex treatment protocols, rising drug-resistant TB (notably multidrug-resistant TB, MDR-TB), and comorbidities. MDR-TB has severely undermined conventional pharmacotherapy, with suboptimal global treatment success rates. Thus, novel strategies are urgently needed to accelerate elimination of Mycobacterium tuberculosis and shorten treatment duration. Immune cell-based therapies, acting through multiple targeted mechanisms, align well with the complex demands of TB treatment. When integrated with advanced technologies such as genetic engineering and nanotechnology, immunotherapy holds substantial promise for developing novel regimens. This review systematically delineates major immune cell types involved and their mechanisms of action, critically assesses current technical bottlenecks, and explores future innovative directions. It also critically evaluates recent encouraging clinical trials in TB immunotherapy. Collectively, these efforts aim to establish a robust theoretical and practical translational framework, overcome existing limitations, accelerate clinical translation of immune cell-based therapies, provide new options for patients, and advance the field toward personalized and precision medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan, 523808, China.
- Dongguan Key Laboratory for Pathogenesis and Experimental Diagnosis of Infectious Diseases, Institute of Laboratory Medicine, School of Medical Technology, Guangdong Medical University, Dongguan, 523808, China.
- Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan, 523808, China; Dongguan…
Förderung
- National Natural Science Foundation of China
- Guangdong Provincial Natural Science Foundation
Zitieren
APA
He, J., Lin, S., Zhang, Q., Chen, R., Lin, X., Lin, B., Li, S., Cong, Y., & Yang, F. (2026). Recent Progresses in Immune Cell Therapy for Tuberculosis. Microbial Pathogenesis, 108915. https://doi.org/10.1016/j.micpath.2026.108915
Vancouver
He J, Lin S, Zhang Q, Chen R, Lin X, Lin B, et al. Recent Progresses in Immune Cell Therapy for Tuberculosis. Microbial Pathogenesis. 2026:108915. doi:10.1016/j.micpath.2026.108915
BibTeX
@article{He2026,
author = {He, Jiawen and Lin, Siqi and Zhang, Qianqian and Chen, Ruixian and Lin, Xiaodan and Lin, Bojie and Li, Shuyi and Cong, Yanguang and Yang, Fen},
title = {Recent Progresses in Immune Cell Therapy for Tuberculosis},
journal = {Microbial Pathogenesis},
year = {2026},
pages = {108915},
doi = {10.1016/j.micpath.2026.108915}
}
EUVIMED